Thalidomide in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
A Phase II Study of Thalidomide in Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck
연구 개요
상세 설명
OBJECTIVES:
I. Determine the effect of thalidomide on survival of patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
II. Determine clinical response rates following this therapy in these patients. III. Determine the toxic effects of thalidomide in these patients. IV. Determine the effect of thalidomide on tumor angiogenesis in these patients.
OUTLINE:
Patients receive 4-20 capsules of oral thalidomide once daily. Dose is escalated in individual patients on a weekly basis for the first 5 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity, or for 12 months past complete response.
연구 유형
등록 (실제)
단계
- 2 단계
연락처 및 위치
연구 장소
-
-
Texas
-
Houston, Texas, 미국, 77030
- University of Texas - MD Anderson Cancer Center
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
DISEASE CHARACTERISTICS:
- Histologically proven squamous cell carcinoma of the head and neck
- Recurrent disease OR metastatic disease at initial diagnosis or at recurrence
- Initial therapy of surgery and/or radiotherapy, induction chemotherapy, or concurrent chemotherapy and radiotherapy allowed
- No more than one prior regimen of chemotherapy or biologic therapy for metastatic disease
- Recurrence after adjuvant or induction chemotherapy may have received one additional course of chemotherapy or biologic therapy
PATIENT CHARACTERISTICS:
- Age: 18 and over
- Performance status: Zubrod 0-2
- Life expectancy: At least 3 months
- WBC at least 3000/mm3
- Platelet count at least 100,000/mm3
- Hematocrit at least 30%
- Bilirubin no greater than 1.5 times normal
- SGOT/SGPT no greater than 1.5 times normal
- Creatinine no greater than 1.5 mg/dL
- Not pregnant or nursing
- Negative pregnancy test
- Fertile women must use 2 methods of effective contraception, 1 barrier and 1 hormonal, beginning at least 4 weeks before study and continuing during and for 1 month after study
- Men must use effective barrier contraception during and for 1 month after study
- No grade 2 or greater peripheral neuropathy
- No serious infection or other concurrent illness requiring immediate therapy
- Must be able to take oral medications
- No medical or social factors that would interfere with compliance
PRIOR CONCURRENT THERAPY:
- Any number of courses of one regimen of chemotherapy allowed
- No concurrent cytotoxic chemotherapy
- No concurrent radiotherapy
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Arm I
Patients receive 4-20 capsules of oral thalidomide once daily.
Dose is escalated in individual patients on a weekly basis for the first 5 weeks.
Treatment continues in the absence of disease progression or unacceptable toxicity, or for 12 months past complete response.
|
공동 작업자 및 조사자
수사관
- 연구 의자: Roy S. Herbst, MD, PhD, M.D. Anderson Cancer Center
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
추가 관련 MeSH 약관
기타 연구 ID 번호
- NCI-2012-02299
- MDA-ID-98270
- NCI-T98-0074
- CDR0000067011 (레지스트리 식별자: PDQ (Physician Data Query))
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .